Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD).
about
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - SummaryPretreatment with ACE inhibitors improves acute outcome of electrical cardioversion in patients with persistent atrial fibrillationCongestive heart failure and diabetes mellitus: balancing glycemic control with heart failure improvementMetabolic syndrome in children with chronic kidney disease and after renal transplantationRenin-Angiotensin-aldosterone system in diabetes and hypertensionMolecular mechanism of endothelial and vascular aging: implications for cardiovascular disease.Skeletal muscle capillary responses to insulin are abnormal in late-stage diabetes and are restored by angiotensin-converting enzyme inhibition.Activation of systemic, but not local, renin-angiotensin system is associated with upregulation of TNF-α during prolonged fasting in northern elephant seal pups.Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndromeAntihypertensive drugs and glucose metabolismVascular smooth muscle insulin resistance, but not hypertrophic signaling, is independent of angiotensin II-induced IRS-1 phosphorylation by JNKPreventive pharmacotherapy in type 2 diabetes mellitus.The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndromeRamipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) studyTherapeutic Challenges in Diabetes Prevention: We Have Not Found the "Exercise Pill"Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.The metabolic syndrome: evolving evidence that thiazolidinediones provide rational therapy.Transgenic mice overexpressing Renin exhibit glucose intolerance and diet-genotype interactionsEffect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis.The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?Heart failure in sub-Saharan Africa: a literature review with emphasis on individuals with diabetes.The role of angiotensin II type 1 receptor blockers in the prevention and management of diabetes mellitus.Candesartan: from left ventricular hypertrophy to heart failure, a global approach.Blood viscosity and hematocrit as risk factors for type 2 diabetes mellitus: the atherosclerosis risk in communities (ARIC) study.Canadian Cardiovascular Society Consensus Conference guidelines on heart failure--2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathiesType 2 diabetes mellitus and heart failure.Diabetes, left ventricular systolic dysfunction, and chronic heart failure.The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection.The sweeter side of ACE2: physiological evidence for a role in diabetes.The beta2 adrenergic receptor Gln27Glu polymorphism affects insulin resistance in patients with heart failure: possible modulation by choice of beta blocker.Review article: Diabetes mellitus and heart failure--an overview of epidemiology and management.Metabolic remodelling in human heart failure.The renin-angiotensin system: a link between obesity, inflammation and insulin resistance.The adipose tissue renin-angiotensin system and metabolic disorders: a review of molecular mechanisms.Cardiogenic diabetes.Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications.Impact of left ventricular assist device on diabetes management: an evaluation through case analysis and clinical impact.Tissue-specific effects of valsartan on rstn and fiaf gene expression in the ob/ob mouse.Computational Drug Repositioning Using Continuous Self-Controlled Case SeriesThe adipose tissue and the involvement of the renin-angiotensin-aldosterone system in cardiometabolic syndrome.
P2860
Q22241786-83609EBD-BD8D-4A76-864E-B4776525667BQ24801156-A210247C-CC6D-4353-8FC8-BDEDC57C8301Q27003819-D55D1DD7-1F9E-4467-89B3-BA24F3E2377FQ27027049-9CE12AB2-6DE9-4813-94A0-800ACBB52567Q28308222-225A5DCA-3359-4F81-867C-64FD88074F4BQ30381121-705F6540-24A0-4459-BDE5-F81E324A6034Q30444650-C940FD05-7F1A-48B4-97B6-1C6E33CB9965Q33817992-6F10AED3-F259-4754-AEDA-979CC0D96733Q33840829-00B9BB55-4262-4EA0-AAAD-6F8C59FE55B4Q33948469-FD8A3C2C-00A1-4C21-806F-D87DABC4B763Q35601355-49B3E64D-A683-4A75-BC44-6ED52E01AC1BQ35686344-4B4CA0CC-539F-420C-BCBB-170EEB950D12Q35850133-01EF8896-44F7-489E-9A5A-B01C27BEF814Q35856525-362EF4F6-ACE0-48CD-9D7F-2CAD4766E496Q35880380-8A2038B6-1907-41A6-80EC-CB070EF4A4D1Q36302833-EF048878-6386-4507-A23D-D1EF6997760AQ36507641-6894D8DA-FA1F-4A52-AE77-C123070B1F8CQ36512685-D42B182E-FF31-4080-AE3B-688936B94BA2Q36582682-B0CED900-E9A9-467C-AA54-0246ADE5FC1CQ36709546-8D187E97-99DB-4B34-91CB-E0B44EC09FB6Q36766997-E30A6BF0-035B-43DE-A7EC-188B65D68260Q36909521-21165BD8-F39E-48AF-90AF-E31E522571ADQ36941825-120C9D0E-BBE3-4BAF-8FBF-A96F4935EE96Q36968690-488BFBF9-998C-4F45-93C5-00B90FD2D4AAQ37061992-2040079E-C6C4-486C-8215-6A81D37131CEQ37069176-5B5340F9-794F-4F47-A374-CF2C16CFF1F0Q37143034-79F34811-0037-4B13-B664-856774BECF1BQ37169716-272F6275-B3D2-46A8-B3C0-7525D138C4E6Q37178255-A9CAD974-99B5-4A00-8FE5-A88E02A1975DQ37233317-9A4980B2-6AA4-465D-BB7D-3E0DBFF6CCCCQ37724505-C16AA819-5170-4749-9389-CFA1F33BCF69Q37849446-5373B2F1-6BD2-49FA-BEC8-EE7B10B3CB29Q37950397-191D6FD0-F7AB-4637-B60E-E80E51A9E231Q38020530-F9F0926B-F7F4-4FBC-AFC5-706A36A8E664Q38156709-01DC162E-75D0-4769-BF15-D43A110063D0Q38170474-EFBFAE3C-4DD6-4207-9970-E5020535F8DBQ38254253-C13D1F7A-E4FB-4844-820C-1CD8A1D87A13Q38343977-5A6957FF-B53D-4F7D-931D-96CBE7FC848DQ38895303-66627586-D9A8-47DC-81FE-3A379331E887Q38979226-E39932EF-DF4E-4159-A717-9D3E2D200813
P2860
Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD).
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Enalapril reduces the incidenc ...... ntricular Dysfunction (SOLVD).
@en
Enalapril reduces the incidenc ...... f Left Ventricular Dysfunction
@nl
type
label
Enalapril reduces the incidenc ...... ntricular Dysfunction (SOLVD).
@en
Enalapril reduces the incidenc ...... f Left Ventricular Dysfunction
@nl
prefLabel
Enalapril reduces the incidenc ...... ntricular Dysfunction (SOLVD).
@en
Enalapril reduces the incidenc ...... f Left Ventricular Dysfunction
@nl
P2093
P1433
P1476
Enalapril reduces the incidenc ...... entricular Dysfunction (SOLVD)
@en
P2093
Anique Ducharme
Emmanuelle Vermes
Jean-Claude Tardif
Michel White
Myriam Lessard
Studies Of Left Ventricular Dysfunction
P304
P356
10.1161/01.CIR.0000054611.89228.92
P407
P577
2003-03-01T00:00:00Z